<SEC-DOCUMENT>0001193125-25-163561.txt : 20250924
<SEC-HEADER>0001193125-25-163561.hdr.sgml : 20250924
<ACCEPTANCE-DATETIME>20250723180428
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-25-163561
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Royalty Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				522154066
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA Corp
		DATE OF NAME CHANGE:	20120119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g16959dsp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Branden Berns</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partner</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1 415.393.4631</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BBerns@gibsondunn.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;23, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>VIA
ELECTRONIC MAIL AND EDGAR FILING </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Mergers and
Acquisitions </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street NE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mr.&nbsp;Blake Grady </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XOMA Royalty Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turnstone Biologics Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule <FONT
STYLE="white-space:nowrap">TO-T</FONT> Filed July&nbsp;11, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by XOMA Royalty Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">File <FONT STYLE="white-space:nowrap">No.&nbsp;005-94123</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Grady: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of XOMA Royalty
Corporation (the &#147;<U>Purchaser</U>&#148;), please find responses to comments received from the Staff of the Division of Corporation Finance (the &#147;<U>Staff</U>&#148;) of the Securities and Exchange Commission (the
&#147;<U>Commission</U>&#148;) by letter dated July&nbsp;18, 2025 (&#147;<U>Letter</U>&#148;), with respect to the Purchaser&#146;s Schedule <FONT STYLE="white-space:nowrap">TO-T</FONT> filed on July&nbsp;11, 2025 (the &#147;<U>Schedule
TO</U>&#148;) and the Offer to Purchase, dated July&nbsp;11, 2025 (the &#147;<U>Offer to Purchase</U>&#148; and, together with the Schedule TO, the &#147;<U>Tender Offer Materials</U>&#148;). Concurrently with delivery of this letter, the Purchaser
filed updated Tender Offer Materials (the &#147;<U>Revised Tender Offer Materials</U>&#148;), including a Schedule <FONT STYLE="white-space:nowrap">TO-T/A</FONT> and revised Offer to Purchase (the &#147;<U>Revised Offer to Purchase</U>&#148;), which
reflect, among other things, revisions to address the Staff&#146;s comments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For your convenience, we have restated below in bold each
comment from the Letter and supplied our responses immediately thereafter. Unless otherwise specified, all references to page numbers and captions correspond to the Offer to Purchase and all capitalized terms used but not defined herein have the
same meaning as in the Tender Offer Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>General </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>We note that the principal business of Purchaser, as described on page
<FONT STYLE="white-space:nowrap">A-1,</FONT> is solely &#147;to consummate the Offer and effect the Merger pursuant to the Merger Agreement, and to perform its obligations under the CVR Agreement.&#148; However, your Schedule TO states that the
principal business of Purchaser is &#147;to engage in any lawful act or activity for which corporations may be organized under the Nevada Revised Statutes,&#148; and Purchaser&#146;s website states that &#147;XOMA is a biotechnology royalty
aggregator &#133; with more than 70 assets.&#148; Please revise to address these apparent discrepancies. Refer to Item 1003(b) of Regulation <FONT STYLE="white-space:nowrap">M-A.</FONT> </B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Gibson, Dunn&nbsp;&amp; Crutcher LLP
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>One Embarcadero Center Suite 2600 | San Francisco, CA 94111-3715 | T: 415.393.8200 | F: 415.393.8306 | gibsondunn.com </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g16959dsp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July 23, 2025</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page
 2
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Response</I>: In response to the Staff&#146;s comment, Purchaser has revised the
disclosure in the Revised Tender Offer Materials&nbsp;to clarify that Purchaser is a Nevada corporation whose primary business is as a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty
payments associated with partnered commercial and <FONT STYLE="white-space:nowrap">pre-commercial</FONT> therapeutic drug candidates (see page&nbsp;2 of the Schedule&nbsp;TO-T/A). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclosure on page <FONT STYLE="white-space:nowrap">A-1</FONT> indicates that &#147;Mr.&nbsp;Burns joined
Purchaser in August 2006.&#148; However, based on disclosure in Item 3 of your Schedule TO, it appears that Purchaser was formed in 2011. Please revise or advise. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Response</I>: In response to the Staff&#146;s comment, Purchaser has revised the disclosure in the Revised Tender Offer Materials to clarify
that Purchaser was incorporated in Delaware in 1981 and redomiciled as a Bermuda-exempted company in December 1998. Effective December&nbsp;31, 2011, Purchaser redomiciled from Bermuda back to Delaware. Purchaser subsequently reincorporated in
Nevada on May&nbsp;30, 2025 (see page&nbsp;2 of the Schedule&nbsp;TO-T/A). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Please disclose the information required by Item 1008(a) and (b)&nbsp;of Regulation <FONT
STYLE="white-space:nowrap">M-A.</FONT> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Response: </I>In response to the Staff&#146;s comment, Purchaser has
revised the disclosure in the Revised Tender Offer Materials to include the following information (see page&nbsp;34 of the Revised Offer to Purchase): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;As of July&nbsp;23, 2025, neither Purchaser nor any of Purchaser&#146;s executive officers and directors beneficially owned any Shares
of Turnstone. No transactions with respect to the Shares have been effected by Purchaser, or, to Purchaser&#146;s knowledge after making reasonable inquiry, any of the directors, executive officers or affiliates of Purchaser, during the 60 days
prior to the date of this Offer to Purchaser.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Refer to the first bullet point under the caption &#147;What Is the CVR and How Does It Work?&#148; on page
2. Please provide illustrative disclosure, in plain English, showing how the CVR Proceeds will be calculated, including how Net Cash Excess and Net Cash Shortfall will be calculated. Refer to Item 1001 of Regulation
<FONT STYLE="white-space:nowrap">M-A</FONT> and to Item 1004(a)(1)(ii) of Regulation <FONT STYLE="white-space:nowrap">M-A.</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Response: </I>In response to the Staff&#146;s comment, Purchaser has revised the first bullet point and included a new second bullet under
the caption &#147;What Is the CVR and How Does It Work&#148; in the Revised Tender Offer Materials with the following language (see page&nbsp;3 of the Revised Offer to Purchase): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;At or prior to the Offer Closing Time, Purchaser, Merger Sub, the rights agent (the &#147;<U>Rights
Agent</U>&#148;) and the representative of the holders of the CVRs (the &#147;<U>Representative</U>&#148;) will enter into the CVR Agreement, governing the terms of the CVRs. Each CVR will represent a
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g16959dsp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July 23, 2025</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page
 3
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
contractual right to receive contingent cash payments equal to a pro rata share of: (i)(a) the net tax receivables from Canadian federal and territory/provincial tax authorities and/or
Qu&eacute;bec Scientific Research and Experimental Development (&#147;SR&amp;ED&#148;) tax credit program as tax refunds up to $850,000 (excluding the $55,610 Qu&eacute;bec SR&amp;ED amount that has been scheduled on Schedule 1.01 of the Merger
Agreement) and (b)&nbsp;the payments received from the landlord under the Sublease, dated November&nbsp;16, 2022, between Turnstone and Medivis, Inc., as a return of security deposit up to $260,000 ((a) and (b)&nbsp;together, the &#147;<U>Legacy
Receivable Amount</U>&#148;), plus (ii)&nbsp;Net Cash Excess (as defined below), if any, and minus (iii)&nbsp;Net Cash Shortfall (as defined below), if any. &#147;<U>Net Cash Excess</U>&#148; means if Final Net Cash is greater than Closing Net Cash
(each as defined in the Merger Agreement and calculated in accordance with Section&nbsp;2.01(c) of the Merger Agreement), then the amount equal to (a)&nbsp;Final Net Cash, minus (b)&nbsp;Closing Net Cash. &#147;<U>Net Cash Shortfall</U>&#148; means
if Final Net Cash is less than Closing Net Cash, then the amount equal to (a)&nbsp;Closing Net Cash, minus (b)&nbsp;Final Net Cash. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For illustrative purposes only, assuming that: (a)&nbsp;Turnstone receives $510,000 in tax refunds from Canadian
tax authorities (i.e., 60% of the maximum refund amount), and $156,000 from Medivis, Inc. as a return of the security deposit under the Sublease Agreement (also 60% of the maximum amount), and (b)&nbsp;Final Net Cash is $3,000,000 and Closing Net
Cash is $3,000,000, such that there is no Net Cash Excess or Net Cash Shortfall, then the aggregate amount payable under the CVRs would be $666,000 or approximately $0.03 per CVR (based on (i) 23,140,691 Shares issued and outstanding, and (ii) 1,135
Shares underlying Turnstone RSUs).&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>On page 3, disclosure indicates that the &#147;offeror estimates that the amount that will be payable (on a <FONT
STYLE="white-space:nowrap">pre-tax</FONT> basis) under the CVRs will be approximately $0.03 per CVR.&#148; Revise the Offer to Purchase to explain the basis for the offeror&#146;s belief with respect to the CVRs. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Response: </I>In response to the Staff&#146;s comment, Purchaser has revised the disclosure in the Revised Tender Offer Materials to explain
the basis for the offeror&#146;s belief with respect to the CVRs (see pages 2 and 3 of the Revised Offer to Purchase): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We cannot
predict whether any CVR Proceeds will be received or, if any CVR Proceeds are received, the amount or timing of any such receipt. In connection with the Offer, the offeror did not engage any independent valuation firm to conduct an analysis of the
potential value of the CVR Proceeds or receive any material <FONT STYLE="white-space:nowrap">non-public</FONT> information assessing the value of the CVR Proceeds. The offeror is relying on Turnstone&#146;s estimate of the CVR Proceeds that would be
payable. <B>Accordingly, in making a decision to tender your Shares in the Offer, you should understand that there can be no assurance whether there will be any payments under the CVR Agreement or with respect to the amount and timing of such
payments (if any). You should also understand that, as discussed below, it is estimated that the amount that will be payable under the CVRs will be approximately $0.03 per CVR. </B>Turnstone has determined that the maximum payout for the CVR is
estimated to be up to $0.05 per CVR, assuming payment in full of the tax refund and lease deposit and no positive or negative adjustment to the CVR Proceeds because of a Net Cash Excess or a Net Cash Shortfall, respectively. After accounting for the
likelihood of different payment scenarios for the tax refund and lease deposit, Turnstone has applied a 40% discount for the tax refund and lease deposit and has assumed no adjustments for net cash calculations under the CVR Agreement. Accordingly,
the probability-weighted estimate of the amount payable is $0.03 per CVR. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g16959dsp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July 23, 2025</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page
 4
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the probability-weighted estimated payout, we note that there can be no
assurance: (i)&nbsp;that Turnstone will receive the tax receivables and/or the return of a lease security deposit prior to the expiration of the CVRs necessary for payment pursuant to the CVRs, (ii)&nbsp;that there will be any positive or negative
adjustments based on the post-closing calculation of Closing Net Cash or (iii) regarding the exact amount of CVR Proceeds or the timing of any such payment, if any. Neither the Merger Agreement nor the CVR Agreement requires Purchaser to use any
efforts in connection with the CVR Proceeds. The discount reflects Turnstone&#146;s assessment of the fair value of the CVRs, taking into account the contingent nature of the payment, the absence of industry benchmarks for similar instruments, and
the inherent uncertainty regarding the receipt of payments for the tax refunds or security deposit. This estimate is subject to change and should not be construed as a prediction or guarantee of actual payments under the CVRs. If any CVR Proceeds
are received after one year following the date of the closing of the Merger, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. Accordingly, in deciding whether to tender your Shares into the Offer, you should understand
that it is possible that no payment will be made pursuant to the CVRs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any further questions or comments, or if you require any additional information, please contact Branden Berns of Gibson,
Dunn&nbsp;&amp; Crutcher LLP, by telephone at (415) <FONT STYLE="white-space:nowrap">393-4631.</FONT> Thank you for your assistance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Owen Hughes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Owen Hughes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Owen Hughes</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Via <FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ryan A. Murr, Gibson, Dunn&nbsp;&amp; Crutcher LLP </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Branden C. Berns, Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Melanie E. Neary, Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sammy Farah, Turnstone Biologics Corp. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g16959dsp69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16959dsp69.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M<NXCP%&EAJ]?+,)CZ%:E5C"4J<*4JU*4G*25HN$8)5-M8.6S1^N]?Q8?LX4
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+@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
